RxDoctor Payments Data

Philip Triffletti, MD

Internal Medicine · Chelsea, MANPI 1861449001

Payments from drug & device makers

$3,375in general payments, 2019–2025

Across 178 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$581
  • AstraZeneca$420
  • Amgen$381
  • Novo Nordisk$371
  • Lilly USA, LLC$326
  • AbbVie$294
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,368100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,375 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$64,993
Medicare patients
126
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$88,890
MounjaroTirzepatide47$51,197
MyrbetriqMirabegron73$33,513
XareltoRivaroxaban23$32,392
JardianceEmpagliflozin23$25,402
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,815
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$18,025
OzempicSemaglutide18$16,823
Breo ElliptaFluticasone/Vilanterol19$10,067
Repatha SureclickEvolocumab13$7,151
VoqueznaVonoprazan Fumarate11$6,870
Estradiol22$3,632
Rosuvastatin Calcium101$3,358
Atorvastatin Calcium248$3,218
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen51$3,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$581$88,89089 claims
Lilly USA, LLCMounjaro$326$51,19747 claims
Astellas Pharma US IncMyrbetriq$28$33,51373 claims
Johnson & JohnsonXarelto$145$32,39223 claims
GSKTrelegy Ellipta, Breo Ellipta$60$29,88245 claims
Boehringer IngelheimJardiance$261$25,40223 claims
AstraZenecaBreztri Aerosphere$420$18,02521 claims
Novo NordiskOzempic$371$16,82318 claims
AbbVieSynthroid$294$1,77420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Chelsea

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →